YOU ARE HERE:
Changing treatments news
page  of 8
 
Headline
Date
  Once-daily darunavir effective and less toxic than twice-daily in experienced patients without prior darunavir resistance: ODIN
18.02.10
  Second-line ART in South Africa shows good results
01.02.10
  New resistance becoming rarer as more patients achieve undetectable HIV viral load
05.01.10
  Most NNRTI-experienced patients in southern Africa will benefit from etravirine
18.12.09
  TB, pregnancy, most common reasons for treatment changes in African study
11.12.09
  Full results of DART lab monitoring study published
09.12.09
  Findings on viral rebound discourage quick drug switches in resource-limited settings
01.12.09
  New EACS guidelines address co-morbidities and diseases of age
16.11.09
  Protease inhibitor monotherapy as a maintenance regimen: are we edging towards acceptance?
16.11.09
  Multiple treatment failures occur less frequently but remain associated with high mortality rates in North American cohort
06.11.09
  Dual maintenance therapy with atazanavir plus raltegravir sustains viral suppression
18.09.09
  Boosted protease inhibitor regimens with 3TC work despite M184V resistance
18.09.09
  Switches to second-line ART occurring faster where viral load testing available
15.09.09
  Delays in switching treatment: NRTI resistance can be slower to emerge than expected
08.09.09
  Boosted darunavir monotherapy works well in two studies
23.07.09
  Boosted and unboosted atazanavir maintain viral suppression equally well
23.07.09
  DART study shows HIV treatment without lab monitoring safe, effective in Africa
21.07.09
  Further evidence of needless treatment switches in absence of viral load testing
13.07.09
  Raltegravir aprobat in SUA pentru tratamentul HIV de prima linie
13.07.09
  Ritonavir-boosted atazanavir as protease-only maintenance therapy: 48-week results
12.03.09

page  of 8